Position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019)

Position statement on use of SGLT-2 inhibitors in tpe 1 diabetes

Discipline:

Diabetes

Clinical taxonomy:

Treatments for diabetes

Resource taxonomy:

Position Paper

Address for correspondence: ABCD (Diabetes Care) Ltd, Miria House, 1683b High Street, Knowle, Solihull, West Midlands, B93 0LL

Telephone: 01675 477602 Facsimile: 01361 331 811 Email: info@abcd.care

ABCD (Diabetes Care) is a company limited by shares in England and Wales under company number 7270377, whose registered address is Sterling House, 1 Sheepscar Court, Meanwood Road, Leeds LS7 2BB. Diabetes Care Trust (ABCD) is a registered charity number 1139057, a company limited by guarantee in England and Wales under company number 74248361,whose registered address is Sterling House, 1 Sheepscar Court, Meanwood Road, Leeds LS7 2BB. ABCD (Diabetes Care) Ltd is a wholly owned subsidiary of the Diabetes Care Trust (ABCD) Ltd

ABCD Corporate Pharma Sponsors; Gold: Napp Pharmaceuticals Limited, Novo Nordisk Ltd, Sanofi Diabetes Silver: Eli Lilly, Takeda UK Ltd Bronze: AstraZeneca UK, Merck Sharp & Dohme Ltd

ABCD Corporate Pump & Device Supporters, Gold: Abbott Diabetes Care, Roche Diabetes Care, Ypsomed Ltd Silver: Medtronic Ltd Bronze: Dexcom, Insulet International Ltd, ViCentra

Read the ABCD statement on pharmaceutical industry funding

Position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019)

Follow Us